Army and air force leadership in the prostate cancer prevention trial

Urology

Volumn 51, Issue 4 SUPPL. A, 1998, Pages 64-66

  Allerton, Jeffrey ^a   Seay, Thomas ^a   Optenberg, Scott ^d   Coltman Jr , Charles A ^c   Higgins, Betsy ^b   Thompson, Ian ^b   Lovato, Laura ^e  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c Southwest Oncology Group   (United States)

^d Ctr Hlthcare Educ Studs A   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AIR FORCE; ARMY; CANCER PREVENTION; CANCER SCREENING; CONFERENCE PAPER; EARLY DIAGNOSIS; HUMAN; LEADERSHIP; MAJOR CLINICAL STUDY; MALE; MILITARY MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR;

ENZYME INHIBITORS; FINASTERIDE; HUMANS; LEADERSHIP; MALE; MIDDLE AGED; MILITARY PERSONNEL; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0031970099     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00058-2     Document Type: Conference Paper

References (17)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. Cancer J Clin. 47:1997;5-27.
2. Crawford ED, Eisenberger M, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med. 321:1989;419-424.
3. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. A Phase I/II study of continuous infusion suramin in patients with hormone refractory prostate cancer toxicity and response . Cancer Chemother Pharmacol. 39:1996;1-8.
4. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial with palliative end points . J Clin Oncol. 14:1996;1756-1764.
5. Crawford ED, Nabors WL. Total androgen blockade American experience . Urol Clin North Am. 18:1991;55-63.
6. Catalona WJ, Smith DS, Ratcliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1991;1156-1161.
7. Kirby RS, Christmas TJ, Brawer M. Prostate Cancer. 1996;129-142 Mosby Publishing, Baltimore, MD.
8. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of localized prostatic cancer a population-based study in 223 untreated patients . Lancet. i:1989;799-803.
9. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen results of the second year . J Urol. 150:1993;106-109.
10. Collins MM, Barry MJ. Controversies in prostate cancer screening analogies to the early lung cancer screening debate . JAMA. 276:1996;1976-1979.
11. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5 alpha-reductase deficiency in man an inherited form of male pseudohermaphroditism . Science. 186:1974;1213-1215.
12. Metcalf BW, Levy MA, Holt DA. Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne. Trends Pharmacol Sci. 10:1989;491-495.
13. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
14. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG. Design of the prostate cancer prevention trial (PCPT). Control Clin Trials. 16:1995;150-163.
15. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 150:1993;379-385.
16. Ries LA, Miller BA, Hankey BF, et al.: SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Bethesda, MD, National Cancer Institute, 1994.
17. Statistical Abstract of the U.S. 1996;357 U.S. Department of Commerce, Washington, DC.